Biblio

Filters: Author is Xu, Kailin [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Qiao J, Liu Y, Wu Y, Li X, Zhu F, Xia Y, Yao H, Chu P, Li H, Ma P, et al. Aberrant expression of RUNX3 in patients with immune thrombocytopenia. Int Immunopharmacol. 2015.

Luo Q, Wei G, Wang X, Xu X, Ju W, Li Z, Gardiner EE, Andrews RK, Zeng L, Xu K, et al. All-Trans Retinoic Acid Impairs Platelet Function and Thrombus Formation and Inhibits Protein Kinase CßI/δ Phosphorylation. Thromb Haemost. 2019.

Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. J Clin Oncol. 2023:JCO2201824.

Zhu S, Xu K, Li S, Yu X, Liu Y, Zhang Q, Zeng L, Xu K, Fu C. Assessment of intestinal status in MPL mutant myeloproliferative neoplasms mice model. Int Immunopharmacol. 2023;125(Pt A):111091.

Zhu S, Li H, Liang J, Lv C, Zhao K, Niu M, Li Z, Zeng L, Xu K. Assessment of oral ciprofloxacin impaired gut barrier integrity on gut bacteria in mice. Int Immunopharmacol. 2020;83:106460.

B

Shao R, Li Z, Xin H, Jiang S, Zhu Y, Liu J, Huang R, Xu K, Shi X. Biomarkers as targets for CAR-T/NK cell therapy in AML. Biomark Res. 2023;11(1):65.

Shi M, Wang J, Huang H, Liu D, Cheng H, Wang X, Chen W, Yan Z, Sang W, Qi K, et al. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nat Commun. 2024;15(1):3371.

Yao Y, Zhang Y, Shi M, Sun Y, Chen C, Niu M, Zhang Q, Zeng L, Yao R, Li H, et al. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. J Leukoc Biol. 2018.

C

Chen W, Su GZ, Xu Y, Guo W, Bhansali R, Pan B, Kong QL, Cheng H, Cao J, Qi K, et al. Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance. Int Immunopharmacol. 2021;94:107503.

Li X, Zhang J, Li Y, Dai Y, Zhu H, Jiang H, Han Y, Chu X, Sun Y, Ju W, et al. Celastrol inhibits platelet function and thrombus formation. Biochem Biophys Res Commun. 2023;693:149366.

Ju W, Lu W, Bao Y, Sun T, Adzraku SYao, Fu C, Qi K, Zhang X, Li Z, Xu K, et al. Clodronate-Liposomes aggravate irradiation -induced myelosuppression by promoting myeloid differentiation. Int J Radiat Biol. 2020:1-24.

Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, Yan Z, Jing G, Pan B, Sang W, et al. Coagulation Disorders after CAR T Cell Therapy: Analysis of 100 Patients with R/R Hematologic Malignancies. Biol Blood Marrow Transplant. 2019.

Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, et al. A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023;14:1169071.

Cheng H, Sun Y, Zhang X, Chen Z, Shao L, Liu J, Wang D, Chen Y, Wang X, Chen W, et al. Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy. Cytotherapy. 2024.

Zeng L, Ding S, Yan Z, Chen C, Sang W, Cao J, Cheng H, Xu K. Correction to: Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2021.

D

Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023.

Chu X, Zhang J, Li Y, Yuan K, Wang X, Gui X, Sun Y, Geng C, Ju W, Xu M, et al. Dimethyl fumarate possesses antiplatelet and antithrombotic properties. Int Immunopharmacol. 2023;120:110381.

E

Adzraku SYao, Cao C, Zhou Q, Yuan K, Hao X, Li Y, Yuan S, Huang Y, Xu K, Qiao J, et al. Endothelial Robo4 suppresses endothelial-to-mesenchymal transition induced by irradiation and improves hematopoietic reconstitution. Cell Death Dis. 2024;15(2):159.

Zhang Y, Liu FA, Liang XL, Zhu J, Han L, Shi XD, Cao J, Li Z, Chen W, Xu K, et al. Expression and prognostic value of C-reactive protein in adult immune thrombocytopenia (ITP) patients. Clin Exp Med. 2023.

I

Zhao K, Ruan S, Tian Y, Zhao D, Chen C, Pan B, Yan Z, Yin L, Zhu S, Xu K. IL-22 promoted CD3+ T cell infiltration by IL-22R induced STAT3 phosphorylation in murine acute graft versus host disease target organs after allogeneic bone marrow transplantation. Int Immunopharmacol. 2016;39:383-388.

Xia J, Li Z, Xu K. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting. J Hematol Oncol. 2023;16(1):60.

Zhong X, Zhu F, Qiao J, Zhao K, Zhu S, Zeng L, Chen X, Xu K. The impact of P2X7 receptor antagonist, brilliant blue G on graft-versus-host disease in mice after allogeneic hematopoietic stem cell transplantation. Cell Immunol. 2016.

Qiao J, Li X, Wu Y, Wu X, Zhu F, Liu N, Qi K, Cheng H, Li D, Sun H, et al. An increased expression profile of Th9/IL-9 correlated with Th17/IL-17 in patients with immune thrombocytopenia. Platelets. 2016:1-8.

L

Zhu S, Zhang X, Xu K, Liang J, Wang W, Zeng L, Xu K. Loss of NLRP6 expression increases the severity of intestinal injury after syngeneic hematopoietic stem cell transplantation. Ann Hematol. 2024.

M

Yang C, Shao T, Zhang H, Zhang N, Shi X, Liu X, Yao Y, Xu L, Zhu S, Cao J, et al. MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. J Transl Med. 2018;16(1):267.

Pages